Elsevier recognizes groundbreaking chemistry research through a new PhD competition
Neuchâtel, Switzerland, 5 February 2010 - Elsevier Properties SA announces the launch of the Reaxys PhD Prize, a competition for candidates currently studying for a PhD or having completed a PhD within the last 12 months.
The prize will be awarded to the candidates that demonstrate excellence in methodology and approach in a peer-reviewed publication. Three prize winners will each receive a check for $2000 and be invited to present their research at the Winners’ Symposium, held at the EuCheMS meeting in Nuremberg, Germany on August 30, 2010.
David Evans PhD, Scientific Affairs Director at Elsevier Properties SA said today: “Reaxys is designed and built around chemists’ needs. With this competition we’re taking this partnership even further.” He continued: “The research being produced by young chemists deserves recognition. We want to celebrate this groundbreaking work and provide scientists with the recognition they deserve.”
All entries will be reviewed by a review board of leading international chemists, chaired by the following members of the Reaxys Advisory Board:
* Dr. P. Kocis - former Global Head Exploratory Chemistry, AstraZeneca
* Professor H. Kunz - University of Mainz, Germany
* Professor H. N. C. Wong - Chinese University of Hong Kong, Hong Kong, China
Submissions will be reviewed based upon originality, innovation, importance to the field, applicability, rigor of approach and publication quality.
All submissions must include a PhD Supervisor letter of recommendation, a CV and a representative peer-reviewed piece of published research. Entries should be submitted by February 28, 2010 here: http://prize.reaxys.com
# # #
About Elsevier Properties SA
Elsevier Properties SA is a center of excellence within Reed Elsevier for the management of intellectual property. Elsevier Properties SA owns the PharmaPendium, Beilstein and Reaxys databases. Trademarks including Reaxys®, PharmaPendium™ and The Lancet® are owned and protected by Elsevier Properties SA and used under license. For additional information see www.reedelsevier.com.
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com
+44 20 3043 4191